Physician profile
Kathryn H Estopinal
NPI 1194275560
$25,344.73
in general payments reported to CMS, 2019-2025
53 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $596 · 2023: $2,324 · 2024: $1,960 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,103 · Travel and Lodging: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,130.00 |
| Food and Beverage | $7,102.64 |
| Travel and Lodging | $3,410.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11,429.63 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Merck Sharp & Dohme LLC | $7,793.74 | 2023-2025 | Welireg, Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $792.11 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Regeneron Healthcare Solutions, INC. | $538.68 | 2022-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $425.96 | 2023-2025 | Erleada, Pipeline, Akeega |
| Gilead Sciences, INC. | $399.11 | 2022-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $398.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $275.66 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Daiichi Sankyo INC. | $256.57 | 2024-2025 | Enhertu, Injectafer, Vanflyta |
| Seagen INC. | $251.34 | 2023 | Tukysa, Padcev |
| Eisai INC. | $212.66 | 2022-2025 | |
| Pfizer INC. | $203.15 | 2022-2025 | |
| Genzyme Corporation | $162.82 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $161.82 | 2021-2025 | |
| Exelixis INC. | $145.69 | 2023-2025 | Cabometyx |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $129.51 | 2022-2024 | Brukinsa |
| Incyte Corporation | $127.79 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $126.18 | 2022-2024 | |
| Kite Pharma, INC. | $116.39 | 2023 | Yescarta |
| Stemline Therapeutics INC. | $111.95 | 2023 | Orserdu |
| Array Biopharma INC | $93.96 | 2022-2025 | Braftovi, Mektovi, Xtandi |
| Ipsen Biopharmaceuticals, INC | $85.45 | 2025 | Onivyde |
| Servier Pharmaceuticals LLC | $83.42 | 2023-2025 | |
| Mirati Therapeutics, INC. | $76.43 | 2023 | Krazati |
| Genentech USA, INC. | $64.20 | 2024-2025 | Itovebi, Perjeta, Tecentriq Hybreza |
| Emd Serono, INC. | $63.76 | 2023-2024 | Bavencio, Tepmetko |
| Tersera Therapeutics LLC | $52.28 | 2023-2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $50.24 | 2024 | Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $48.78 | 2023 | Ninlaro |
| Avyxa Pharma, LLC | $46.38 | 2025 | |
| Aveo Pharmaceuticals, INC. | $43.88 | 2024 | |
| Caris Mpi, INC. | $43.53 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $42.32 | 2025 | Ayvakit |
| Glaxosmithkline, LLC. | $41.92 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Celgene Corporation | $39.13 | 2022-2023 | Reblozyl |
| Coherus Oncology, INC. | $33.56 | 2024-2025 | Loqtorzi |
| Amgen INC. | $30.67 | 2022-2023 | Lumakras |
| Puma Biotechnology, INC. | $30.44 | 2022-2025 | |
| Tempus Ai, INC | $29.56 | 2024 | |
| Lilly USA, LLC | $25.77 | 2024 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $24.59 | 2023 | Imbruvica |
| Cumberland Pharmaceuticals, INC. | $24.39 | 2024 | Sancuso |
| Springworks Therapeutics, INC. | $23.42 | 2025 | Ogsiveo |
| G1 Therapeutics, INC. | $21.87 | 2023 | Cosela |
| Genmab U.S., INC. | $21.46 | 2024 | Epkinly |
| Verity Pharmaceuticals INC. | $21.33 | 2024 | Trelstar |
| Organon LLC | $19.48 | 2023 | Ontruzant |
| Cti Biopharma Corp. | $18.94 | 2023 | Vonjo |
| Accord Healthcare, INC. | $18.50 | 2025 | |
| Beone Medicines USA, INC. | $17.63 | 2025 | Brukinsa |
| Kyowa Kirin, INC. | $16.36 | 2024 | Poteligeo |
| Taiho Oncology, INC. | $16.20 | 2023 | |
| Rigel Pharmaceuticals, INC. | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Estopinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.